Recombinant human VEGF receptor-Fc fragment fusion protein (Tiantai Yinkang)
重组人VEGF受体-Fc融合蛋白（天台银康生物）
Report date: 2022/07/19 16:22:54
Base Information
Drug NameRecombinant human VEGF receptor-Fc fragment fusion protein (Tiantai Yinkang)
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTiantai Yinkang Biological Medicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesTiantai Yinkang Biological Medicine Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A